Pharmaceutical sector: suspected anti-competitive agreements and conduct

The CMA is investigating alleged anti-competitive agreements and conduct in the pharmaceutical sector under Chapters I and II CA98 and Articles 101 and 102 TFEU.

Case timetable

Date Action
July 2018 to October 2018 Further investigation including further information requests. CMA analysis and review of information gathered
July 2018 Decision taken to proceed with investigation
October 2017 to June 2018 Initial investigation and information gathering. CMA analysis and review of information gathered
October 2017 Investigation opened

Change log

The following changes have been made to the case timetable since it was first published in October 2017:

Date of change Reason for change Change made to timetable
19 April 2018 Additional time needed to gather and analyse additional information Date for completing initial investigation and information gathering changed from April 2018 to June 2018

Case information

On 10 October 2017, the CMA launched an investigation under Chapters I and II of the CA98 and Articles 101 and 102 of the TFEU into suspected breaches of competition law by various parties. The investigation relates to alleged anti-competitive agreements and/or concerted practices and suspected abuse of dominance in relation to generic pharmaceutical products.

The CMA has not reached a view on whether there is sufficient evidence of an infringement of competition law for it to issue a statement of objections to the parties under investigation. Not all cases result in the CMA issuing a statement of objections.


Project Directors

Susan Oxley (020 3738 6365,

Brian Jackson (020 3738 6546,

Senior Responsible Officer

Geoff Steadman (020 3738 6311,

Published 13 October 2017
Last updated 13 July 2018 + show all updates
  1. Case timetable updated.
  2. Case timetable updated.
  3. First published.